Key Drivers
- High Gross Margin
- Negative Cash Flow
- Rising Leverage
AIAI Summary
AXSM has shifted from a pipeline-only story to a real commercial growth case, with AUVELITY and SUNOSI driving strong revenue acceleration and added optionality from dementia-agitation and AXS-12, but the key takeaway is still neutral: until revenue growth starts translating into operating leverage, persistent losses, cash burn, and dilution risk keep the stock's upside from being fully de-risked.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Gross Margin
- •Negative Cash Flow
- •Rising Leverage
AXSM's high gross margins and solid cash position are offset by persistent operating losses, negative free cash flow, rising leverage, and dilution, keeping the financial outlook pressured. ക ക
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Base forming
- •Rebound capped
AXSM has shifted into a short-term downtrend after peaking near $241, but the $210–$221 range is acting as a tentative base that needs a clear move back above $221 to improve, while a drop below $210 would likely weaken the setup.
Sharp drop from the mid-$230s to about $218 after late-July selling pressure
Sentiment & News
Key News Insights:
- •Revenue growth
- •Cost pressure
- •Pipeline expansion
Axsome posted strong revenue growth driven by AUVELITY and new launches, but rising costs and mixed sentiment kept profitability under pressure despite ongoing pipeline progress.
The stock may stay volatile as commercial momentum and pipeline progress are offset by higher spending, mixed earnings signals, and insider selling
Similar Companies in Healthcare
Other companies in the same sector with AI ratings